IRF4 and plasma cell myeloma: Additionally, we proposed several novel potential pathways dysregulated by CLF treatment in myeloma, including induction of ER stress, autophagy, mitochondrial dysfunction, oxidative phosphorylation, enhancement of the downstream cascade of p65-NFkB-IRF4-Myc downregulation, and ROS-dependent apoptotic cell death [13].